Secondary Hypogonadism: Commonly Missed Diagnoses and How to Manage It

What the lab pattern has to show

FDA's testosterone labels divide hypogonadism into two patterns. In primary hypogonadism the testes fail, from causes such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals, and FSH and LH usually sit above the normal range. In hypogonadotropic (secondary) hypogonadism the defect is gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma or radiation, and FSH and LH are in the normal or low range [1].

The Endocrine Society guideline follows the same logic: once deficiency is confirmed, further testing is done to find the cause, including LH and FSH to separate primary from secondary hypogonadism [2].

A normal-range LH or FSH result does not rule out secondary hypogonadism when testosterone is low. In the secondary pattern, gonadotropins inside the reference range are part of the picture the labels describe [1].

Why the diagnosis gets missed

One low value, no confirmation

The Endocrine Society recommends diagnosing hypogonadism only in men with symptoms and signs consistent with testosterone deficiency and unequivocally and consistently low serum testosterone, starting with a fasting morning total testosterone on an accurate assay and confirming it by repeating the measurement [2]. The AUA guideline sets a total testosterone below 300 ng/dL as a reasonable cutoff and requires two measurements on separate occasions, both early in the morning; a single low value, or symptoms alone, is not enough [3]. The Testim and Depo-Testosterone labels give a similar instruction in their dosing sections, requiring morning measurements on at least two separate days, below the normal range, before treatment starts [1][11].

Cut points that do not agree

Total testosterone is read against a range, and the range depends on the assay and the guideline. In 9,054 men from four cohort studies, cross-calibrated to a CDC reference method, healthy non-obese men aged 19 to 39 had a total testosterone range of 264 to 916 ng/dL (2.5th to 97.5th percentile), with a 5th percentile of 303 ng/dL and a median of 531 ng/dL. Much of the variation between cohorts came from assay differences [4]. That leaves two cut points in circulation: about 264 ng/dL as the harmonized lower limit of the young healthy range, and 300 ng/dL as the AUA diagnostic cutoff [4][3].

Overlap with depression

Low testosterone and depressive illness can overlap. In a study of 748 men aged 50 or older without a prior diagnosis of depressive illness followed for 2 years, men with low testosterone had a higher incidence of depressive illness, 18.5% versus 10.4%, and a shorter time to onset, with an adjusted hazard ratio of 2.1 (95% CI 1.3 to 3.2) [12]. The study reported an association and called for further prospective studies [12].

Blamed on age

In the Baltimore Longitudinal Study of Aging, testosterone and SHBG were measured in stored samples from 890 men. The longitudinal decline averaged 0.124 nmol/L per year, and the proportion of men with hypogonadal total testosterone was about 20% over age 60, 30% over 70 and 50% over 80 [13]. Low values are therefore frequent in older men, but FDA states that approved testosterone products are for men with low testosterone plus an associated medical condition, and that none is approved for men with low testosterone who lack such a condition [14]. Labels still carry a limitation of use for age-related (late-onset) hypogonadism, although in June 2026 FDA requested that the limitation be removed and that prostate cancer and benign prostatic hyperplasia information be revised; whether each manufacturer has updated its label yet is not confirmed [14][11].

Causes that get left off the list

Obesity and type 2 diabetes

A 2011 review of low testosterone in men with type 2 diabetes reports that low testosterone is commonly associated with type 2 diabetes and the metabolic syndrome, that the difference from men without diabetes is moderate and comparable in size to the effect of other chronic diseases, and that the relationship with visceral fat runs in both directions [5]. The same review notes that about one third of U.S. men aged 65 or older have diabetes, with a similar percentage having low testosterone levels [5]. Its conclusion for the overweight man with type 2 diabetes and a subnormal testosterone is lifestyle change, meaning weight loss and exercise, which raise testosterone when they succeed; it stated that testosterone therapy should not be given to such men until benefits and risks are clarified by adequately powered trials [5].

Chronic opioid therapy

A review describes opioid-related hormonal effects as apparently common and notes that symptoms may go unreported, particularly among patients taking the equivalent of at least 100 mg of morphine daily [6]. Its list of effects includes reduced sexual function, decreased libido, infertility, mood disorders and osteoporosis [6]. The management options it lists are discontinuing opioid therapy, reducing the dose, switching to a different opioid, and hormone supplementation [6].

Congenital GnRH deficiency

Congenital hypogonadotropic hypogonadism is rare, has more than 25 causal genes identified to date, and is characterized by absent puberty and infertility. About 50% of patients have anosmia or hyposmia, which is Kallmann syndrome, and 10 to 20% show spontaneous recovery of reproductive function [7].

Structural pituitary and hypothalamic disease

Tumors, trauma and radiation affecting the pituitary or hypothalamus are named in the labels as causes of the secondary pattern [1].

Separating secondary from primary

When total testosterone is near the lower limit of normal, or a condition alters sex hormone-binding globulin, the Endocrine Society recommends free testosterone by equilibrium dialysis or an accurate formula [2]. Once deficiency is confirmed, LH and FSH separate the secondary pattern from the primary one [2][1]. The guideline does not recommend screening the general population [2].

Management: the fertility question comes first

Exogenous testosterone suppresses spermatogenesis, and the Endocrine Society recommends against starting it in men planning fertility in the near term; the AUA position is that it should not be prescribed to men currently trying to conceive [2][3]. A review of treatment in men of reproductive age describes the mechanism as suppression of intratesticular testosterone, which is required for normal spermatogenesis, and notes that in studies of hormonal contraception most men regained normal sperm production within 1 year of stopping [15].

Options that act upstream

hCG is FDA-approved for selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males, and for prepubertal cryptorchidism not due to anatomic obstruction [8][16]. In congenital hypogonadotropic hypogonadism, fertility can be induced in most patients with specialized regimens [7].

Clomiphene citrate is FDA-approved only for ovulatory dysfunction in women, so its use in men with low testosterone is off-label [10]. The 2013 review describes off-label selective estrogen receptor modulators such as clomiphene as effective for maintaining testosterone production long term and does not recommend routine aromatase inhibitor use given the lack of long-term data [15]. Enclomiphene is not an FDA-approved drug in any form [9], and anastrozole is approved for breast cancer in postmenopausal women, not for male hypogonadism [17].

Testosterone replacement when fertility is not the goal

Testosterone labels are written for replacement therapy in males with primary or hypogonadotropic hypogonadism [1].

Testosterone replacement is available in several forms. Aveed is an approved testosterone undecanoate injection [18]; Testim is a topical gel [1], Depo-Testosterone is an intramuscular injection [11], Testopel is a pellet [19], and Methitest is oral methyltestosterone [20]. The Depo-Testosterone label gives a replacement dose of 50 to 400 mg every two to four weeks [11]. Aveed is available only through a restricted program because of pulmonary oil microembolism and anaphylaxis, and patients are observed for 30 minutes after each injection [21].

Boxed warnings are not identical across the class. FDA's 2/28/2025 labeling action removed language about increased cardiovascular risk from the Boxed Warning of all testosterone products [22]. The topical gels Testim and Vogelxo keep a secondary exposure boxed warning, Aveed keeps its POME and anaphylaxis warning, and Depo-Testosterone and the generic cypionate and enanthate injections have no boxed warning [22][1].

The TRAVERSE trial randomized 5,246 men aged 45 to 80 with hypogonadism symptoms, two fasting testosterone levels below 300 ng/dL and existing or high cardiovascular risk to 1.62% transdermal testosterone gel or placebo. A first major cardiovascular event occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo, hazard ratio 0.96 (95% CI 0.78 to 1.17), meeting noninferiority; atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone [23].

The Endocrine Society recommends against starting therapy in men who have breast cancer or prostate cancer, a palpable prostate nodule or induration, PSA above 4 ng/mL, PSA above 3 ng/mL with increased prostate cancer risk and no urological evaluation, elevated hematocrit, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure, myocardial infarction or stroke within the last 6 months, or thrombophilia [2].

For men aged 65 or older with symptoms and consistently low morning levels, the guideline suggests an individualized discussion of risks and benefits rather than routine prescribing, and it recommends against using testosterone to improve glycemic control in type 2 diabetes [2]. The American College of Physicians suggests discussing testosterone only for men with age-related low testosterone and sexual dysfunction who want better sexual function, reevaluating within 12 months and stopping if sexual function does not improve, considering intramuscular rather than transdermal formulations, and not starting it for energy, vitality, physical function or cognition [24].

Monitoring on therapy

The Endocrine Society aims for mid-normal testosterone concentrations and, in the first year, reviews symptoms, adverse effects and adherence, measures serum testosterone and hematocrit, and evaluates prostate cancer risk [2]. AUA guidance is to recheck testosterone every 6 to 12 months while on therapy [3]. The Testim label says to check hematocrit before starting, again 3 to 6 months after starting and then annually, to stop therapy until hematocrit decreases if it becomes elevated, and to monitor blood pressure periodically [1]. Testosterone is a Schedule III controlled substance [11].